Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 5 od 190  
Back povratak na rezultate
2020, vol. 77, br. 4, str. 426-430
Imunohistohemijska ekspresija androgenih receptora kod karcinoma prostate i benigne hiperplazije prostate
aUniverzitet u Novom Sadu, Medicinski fakultet, Katedra za patologiju + Klinički centar Vojvodine, Centar za patologiju i histologiju, Novi Sad
bUniversity of Novi Sad, Faculty of Medicine, Department of surgery + Klinički centar Vojvodine, Klinika za urologiju, Novi Sad
cKlinički centar Vojvodine, Centar za patologiju i histologiju, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet, Katedra za histologiju i embriologiju

e-adresasandra.trivunic-dajko@mf.uns.ac.rs
Ključne reči: prostata, neoplazme; receptori, androidni; prostata, hiperplazija; imunohistohemija
Sažetak
Uvod/Cilj. Karcinom prostate (PCa), kao i njegov ishodišni organ se nalaze pod uticajem hormona, što je iskorišćeno u terapijske svrhe. Androgeni preko androgenih receptora (AR) utiču na ćelijski rast i funkciju, proliferaciju, diferencijaciju, apoptozu, lipidni metabolizam i sekretornu aktivnost prostate, ali i na razvoj i progresiju PCa. Antiandrogena terapija se sprovodi kod bolesnika sa metastaskim PCa, upravo sa ciljem da blokira dejstvo androgena. Imunohistohemijskom analizom AR u tkivu prostate sa karcinomom, možemo da pretpostavimo kako će tumor reagovati na datu antiandrogenu terapiju, bilo da se radi o androgen pozitivnim ili androgen negativnim, rezistentnim tumorima. Saznanja o zastupljenosti AR u tkivu tumora mogla bi poslužiti kao prognostički indikator u patohistološkoj analizi. Cilj rada je bio evaluacija ekspresije AR kod bolesnika sa benignom hiperplazijom (BHP) i kod bolesnika sa PCa, pre sprovedene terapije. Metode. Imunohistohemijska analiza je sprovedena uz upotrebu anti-human AR monoclonal antibody AR441 (DAKO), uz semikvantitativnu procenu prisustva i inteziteta AR kod 195 bolesnika, 165 sa BHP i 30 sa PCa. Materijal je dobijen iglenom biopsijom ili transuretralnom resekcijom prostate (TURP). Rezultati. Sve sekretorne ćelije kod bolesnika sa BHP su bile intezivno androgen pozitivne, dok su kod bolesnika sa PCa, mahom bile umereno do izrazito pozitivne, ali sa fokusima negativnosti. Uočena je negativna korelacija AR sa Gleason skorom i International Society of Urologic Pathology (ISUP) gradus grupom PCa, koja nije bila statistički značajna. Zaključak. Rezultati studije su pokazali da je PCa, pre sprovedene terapije, androgen zavisan sa visokim stepenom ekspresije AR.
Reference
Attard, G., Cooper, C.S., de Bono, J.S. (2009) Steroid hormone receptors in prostate cancer: A hard habit to break?. Cancer Cell, 16(6), 458-462
Bortticelli, A.R., Pitino, A., Botticelli, D. (2002) Expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica, 94(2), 107-111
Gordetsky, J., Epstein, J. (2016) Grading of prostatic adenocarcinoma: Current state and prognostic implications. Diagnostic Pathology, 11(1), 25-33
Hanahan, D., Weinberg, R.A. (2011) Hallmarks of cancer: The next generation. Cell, 144(5), 646-674
Hansson, J., Abrahamsson, P.A. (2001) Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Annals of Oncology, 12(2), S145-S152
Heinlein, C.A., Chang, C. (2004) Androgen receptor in prostate cancer. Endocrine Reviews, 25(2), 276-308
Horwich, A., Parker, C., de Reijke, T., Kataja, V., ESMO Guidelines Working Group (2013) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24(Suppl 6), vi106-114
Hudes, G.R. (2002) Signaling inhibitors in the treatment of prostate cancer. Invest New Drugs, 20(2), 159-172
Huggins, C., Hodges, C.V. (1972) Studies on prostatic cancer I: The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians, 22(4), 232-240
Li, R., Wheeler, T., Dai, H., Frolov, A., Thompson, T., Ayala, G. (2004) High level of androgen receptor is associated with aggressive clinicopathological feature and decreased biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology, 28(7), 928-934
Noordzij, M.A., Bogdanowicz, J.F.A.T., van Krimpen, C., van der Kwast, T.H., van Steenbrugge, G.J. (1997) The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients. Journal of Urology, 158(5): 1880-1885, Department of Urology, Erasmus University, Rotterdam, Netherland
Osman, W.M., Abd, E.A.R.M., Abou, G.H.H. (2013) DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: A possible role in carcinogenesis. Journal of the Egyptian National Cancer Institute, 25(4), 223-230
Poelaert, F., van Praet, C., Beerens, A.S., de Meerleer, G., Fonteyne, V., Ost, P., Lumen, N. (2015) The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: A pilot study. BioMed Research International, 2015, 812815
Qui, Y.Q., Lauschner, I., Braun, P.M. (2008) Androgen receptor expression in clinically localized prostate cancer: Immunohistochemistry study and literature review. Asian J Androl, 10(6), 855-863
Renzo, A., Botticelli, A., Pitino, A., Botticelli, A.R., Zaffe, D. (2002) Prognostic relationship between immunohistochemical expression of neuroendocrine cells, androgen receptors and angiogenesis in prostate carcinoma. Pathologica, 94(2), 109-112
Segawa, N., Mori, I., Utsunomiya, H., Nakamura, M., Nakamura, Y., Shan, L., Kakudo, K., Katsuoka, Y. (2001) Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathology International, 51(6), 452-459
Takeda, H., Akakura, K., Masai, M., Akimoto, S., Yatani, R., Shimazaki, J. (1996) Androgen receptor content of the prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer, 77(5), 934-940
Tamburrino, L., Salvianti, F., Marchiani, S., Pinzani, P., Nesi, G., Serni, S., Forti, G., Baldi, E. (2012) Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens. Steroids, 77(10), 996-1001
Theodoropoulos, V.E., Tsigka, A., Mihalopoulou, A., Tsoukala, V., Lazaris, A.C., Patsouris, E., Ghikonti, I. (2005) Evaluation of the neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: Prognostic implications. Urology, 66(4), 332-337
Trivunić, S., Budakov, P., Vučković, N., Živojinov, M. (2007) Morphological parameters of prostatic adenocarcinoma. Medicinski pregled, vol. 60, br. 11-12, str. 549-552
Vojinov, S., Levakov, I., Jeremić, D., Živojinov, S., Marušić, G. (2011) Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade. Vojnosanitetski pregled, vol. 68, br. 4, str. 321-326
Wein, A.J., Kavoussi, L.R., Novick, A.C., Partin, A.W., Peters, C.A. (2011) Hormonal therapy for prostate cancer. u: Berman D.M. [ur.] Campbell-Walsh Urology, Philadelphia, PA: WB Saunders, 10th ed
Wein, A.J., Kavoussi, L.R., Novick, A.C., Partin, A.W., Peters, C.A. (2011) Molecular biology and physiology of the prostate. u: Berman D.M. [ur.] Campbell-Walsh Urology, Philadelphia, PA: WB Saunders, 10th ed
Wetherill, Y.B., Petre, C.E., Monk, K.R., Puga, A., Knudsen, K.E. (2002) The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther, 1(7), 515-524
Wikström, P., Marusic, J., Stattin, P., Bergh, A. (2009) Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate, 69(8), 799-809
World Health Organization (2016) World health statistics 2016: Monitoring health for the SDGs. www.who.int/gho/publications/world_health_statistics/2016/en
Zhou, M., Netto, G., Epstein, J. (2012) Uropathology: High-yerld pathology. Philadelphia, PA: Elsevier
 

O članku

jezik rada: engleski
vrsta rada: kratki članak
DOI: 10.2298/VSP170629083T
objavljen u SCIndeksu: 14.05.2020.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0